<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989257</url>
  </required_header>
  <id_info>
    <org_study_id>4-2021-0591</org_study_id>
    <nct_id>NCT04989257</nct_id>
  </id_info>
  <brief_title>24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial</brief_title>
  <official_title>24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective randomized clinical trial is to compare the clinical outcomes&#xD;
      between aspirin with ticagrelor versus aspirin with clopidogrel in high ischemic risk&#xD;
      patients beyond 12 months after percutaneous coronary intervention with drug-eluting stent&#xD;
      implantation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Ticagrelor-based dual-antiplatelet therapy vs. Clopidogrel-based dual-antiplatelet therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all-cause death, myocardial infarction, or stroke</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Composite of all-cause death, myocardial infarction, or stroke at 24 months after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BARC type 2, 3, or 5 bleeding</measure>
    <time_frame>up to 24 months</time_frame>
    <description>BARC type 2, 3, or 5 bleeding at 24 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>up to 24 months</time_frame>
    <description>All-cause death at 24 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Myocardial infarction at 24 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Stroke at 24 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Cardiac death at 24 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause death, myocardial infarction, stroke, or BARC type 2, 3, or 5 bleeding</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Composite of all-cause death, myocardial infarction, stroke, or BARC type 2, 3, or 5 bleeding at 24 months after randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3488</enrollment>
  <condition>High Ischemic Risk</condition>
  <arm_group>
    <arm_group_label>Ticagrelor-based dual-antiplatelet therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin with ticagrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel-based dual-antiplatelet therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin with clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor-based dual-antiplatelet therapy</intervention_name>
    <description>Aspirin with ticagrelor</description>
    <arm_group_label>Ticagrelor-based dual-antiplatelet therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel-based dual-antiplatelet therapy</intervention_name>
    <description>Aspirin with clopidogrel</description>
    <arm_group_label>Clopidogrel-based dual-antiplatelet therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥50 years old&#xD;
&#xD;
          2. History of drug-eluting stent implantation due to acute myocardial infarction 12 to 24&#xD;
             months ago&#xD;
&#xD;
          3. High-risk for ischemic events (at least one of the following) 1) Age &gt;65 years old 2)&#xD;
             Medical treatments for diabetes mellitus 3) Multi-vessel coronary artery disease 4)&#xD;
             More than 2 episodes of myocardial infarction 5) Chronic kidney disease (stage III or&#xD;
             IV)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age ≥85 years old&#xD;
&#xD;
          2. Pregnant women or women with potential childbearing&#xD;
&#xD;
          3. Life expectancy &lt; 1 year&#xD;
&#xD;
          4. Inability to understand or read the informed consent&#xD;
&#xD;
          5. Need for long-term anticoagulation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byeong-Keuk Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Byeong-Keuk Kim</last_name>
    <phone>82-2-2228-8460</phone>
    <email>kimbk@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Byeong-Keuk Kim</last_name>
      <phone>82-2-2228-8460</phone>
      <email>kimbk@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

